ERBB2 and neoplasm: These results were recently confirmed in a pooled analysis of a large cohort of 3771 patients receiving NAC from the German Breast Group [5], showing that the relationship between tumor-infiltrating lymphocyte (TIL) levels and pCR translated into a disease-free survival advantage in HER2-positive and TNBC tumors.